G. Moore

发表

Photoaffinity labelling of angiotensin receptors: functional studies on responding tissues.

G. Moore, 1987, Pharmacology & therapeutics.

Design and synthesis of potent tyr(OMe)5-gonadotropin-releasing hormone (GnRH) analogues with modifications at positions 6, 9 and 10

G. Moore, H. Habibi, J. Matsoukas, 1998, Letters in Peptide Science.

Fluorescence properties of angiotensin II analogues in receptor-simulating environments: relationship between tyrosinate fluorescence lifetime and biological activity.

G. Moore, J. Matsoukas, R. Turner, 1991, Biochimica et biophysica acta.

Design and synthesis of thrombin receptor-derived nonpeptide mimetics utilizing a piperazine scaffold.

M. Hollenberg, G. Moore, J. Matsoukas, 1999, Bioorganic & medicinal chemistry.

A new approach to angiotensin antagonists: methylation of the tyrosine hydroxyl in angiotensin II.

G. Moore, J. Matsoukas, M. N. Scanlon, 1984, Life sciences.

Vascular actions of thrombin receptor peptide.

M. Hollenberg, G. Moore, I. Muramatsu, 1992, Canadian journal of physiology and pharmacology.

Biological activity of the novel cyclic angiotensin II analogue [Sar1,Lys3,Glu5]ANG II

E. Iliodromitis, G. Moore, D. Kremastinos, 1996, Letters in Peptide Science.

Discovery and design of novel inhibitors of botulinus neurotoxin A: targeted ‘hinge’ peptide libraries

G. Moore, J. Hayden, Samir S. Roy, 2003, Journal of applied toxicology : JAT.

Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy

V. Apostolopoulos, G. Moore, J. Matsoukas, 2022, Viruses.

Attenuation of intestinal and cardiovascular anaphylaxis by the salivary gland tripeptide FEG and its d-isomeric analog feG

G. Moore, J. Davison, R. Mathison, 1998, Peptides.

Submandibular gland peptide‐T (SGP‐T): Modulation of endotoxic and anaphylactic shock

G. Moore, J. Davison, R. Mathison, 1997 .

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System

G. Moore, J. Bojarska, J. Matsoukas, 2022, Molecules.

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19

V. Apostolopoulos, G. Moore, J. Matsoukas, 2021, Biomolecules.

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy

V. Apostolopoulos, G. Moore, J. Matsoukas, 2021, Molecules.

Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2

Christos T. Chasapis, V. Apostolopoulos, G. Moore, 2022, Biomedicines.

“Hinge” peptide libraries in basic research and drug development: Application to breast cancer and multiple sclerosis

G. Moore, 1997 .

Inhibition of enzymatic degradation of angiotensin II in membrane binding assays: utility of 1,10-phenanthroline.

G. Moore, P. Koziarz, 1990, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Classification of angiotensin receptors in rat isolated uterus, portal vein, and aorta using a slowly dissociating antagonist [Sar1,Ile8]ANG II for receptor blockade.

G. Moore, M. N. Scanlon, 1988, Journal of pharmacological methods.

I. 1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): Clustering of the aromatic rings in dimethylsulfoxide

G. Moore, J. Matsoukas, G. Bigam, 1990, Peptides.

Hinge peptide combinatorial libraries for inhilbitors of botulinum neurotoxins and saxitoxin: Deconvolution strategy

William E Lee, W. E. Lee, G. Moore, 2006, Molecular diversity.

Kinetics of acetylation-deacetylation of angiotensin II. Intramolecular interactions of the tyrosine and histidine side-chains.

G. Moore, 2009, International journal of peptide and protein research.

Action of thrombin receptor polypeptide in gastric smooth muscle: identification of a core pentapeptide retaining full thrombin-mimetic intrinsic activity.

M. Hollenberg, G. Moore, M. Saifeddine, 1992, Molecular pharmacology.

Angiotensin as a model for hormone — receptor interactions

G. Moore, J. Matsoukas, John M. Matsoukas, 1985, Bioscience reports.

Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus.

G. Moore, D. Schlesinger, K. Lederis, 1982, Science.

The relationship between homotropic and heterotropic cooperativity for angiotensin receptors in smooth muscle.

G. Moore, M. N. Scanlon, P. Koziarz, 1990, General pharmacology.

Comparison of angiotensin receptors in isolated smooth muscle tissues by photoaffinity labelling.

G. Moore, Y. Kwok, Yan G. Kwok, 1985, European journal of pharmacology.

Toxin inhibition - deconvolution strategies and assay screening of combinatorial peptide libraries

William E Lee, W. E. Lee, Armando J. Marenco, 2007 .

Putative precursors of vasopressin, oxytocin, and neurophysins in the rat hypothalamus.

G. Moore, W. North, J. Rosenior, 1981, Endocrinology.

A Highly Specific Antiserum for Arginine Vasopressin1

G. Burford, G. Moore, A. Lutterodt, 1977 .

Reciprocal modulation of the binding of angiotensin agonists and antagonists to angiotensin receptors in smooth muscle.

G. Moore, J. Beck, P. Koziarz, 1993, General pharmacology.

Synthesis and biological activities of angiotensin II and Sarmesin analogues containing cyclohexylalanine.

G. Moore, J. Matsoukas, P. Cordopatis, 2009, International journal of peptide and protein research.

Removal of protected peptides from the Merrifield resin by potassium cyanide catalyzed transesterification.

G. Moore, D. Mcmaster, 2009, International journal of peptide and protein research.

The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.

T Mavromoustakos, G. Moore, J. Matsoukas, 2000, Bioorganic & medicinal chemistry.

II. 1H-NMR studies of sarmesin and [des1]sarmesin conformation in dimethylsulfoxide by nuclear Overhauser effect (NOE) enhancement spectroscopy: Folding of the N- and C-terminal domains

G. Moore, J. Matsoukas, John M. Matsoukas, 1990, Peptides.

Properties of urophysial proteins (urophysins) from the white sucker, Catostomus commersoni

G. Burford, G. Moore, K. Lederis, 1975, Molecular and Cellular Endocrinology.

Capillary electrophoresis laser-induced fluorescence for screening combinatorial peptide libraries in assays of botulinum neurotoxin A.

William E Lee, W. E. Lee, Armando J. Marenco, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Actions of thrombin and thrombin receptor peptide analogues in gastric and aortic smooth muscle: development of bioassays for structure-activity studies.

M. Hollenberg, G. Moore, M. Saifeddine, 1992, Life sciences.

Conformational Analysis of the Thrombin Receptor Agonist Peptides SFLLR and SFLLR-NH2 by NMR: Evidence for a Cyclic Bioactive Conformation

M. Hollenberg, G. Moore, J. Matsoukas, 1997, Journal of protein chemistry.

Cyclic thrombin receptor-derived peptide analogues containing D-Phe and D-Arg

M. Hollenberg, G. Moore, J. Matsoukas, 1995 .

Influence of polyfluorination of the phenylalanine ring of angiotensin II on conformation and biological activity.

G. Moore, J. Matsoukas, P. Bovy, 1991, Biochimica et biophysica acta.

Extended chain analogs of [arginine8]vasopressin as model prohormones: investigation of precursor-processing enzymes in extracts of the rat hypothalamus and neural lobe.

D. Severson, G. Moore, Y. Kwok, 1982, Endocrinology.

Failure of neurohypophysial neurosecretory granule lysate to liberate arginine-vasopressin from synthetic model prohormones simulating covalent attachment or arginine-vasopressin to neurophysin.

G. Moore, K. Lederis, R. W. Swann, 1977, The Journal of endocrinology.

An arginine vasotocin-like neuropeptide is present in the nervous system of the marine mollusc Aplysia californica

K. Lukowiak, G. Moore, K. Lederis, 1981, Brain Research.

Angiotensinogen-like epitopes are present in the CNS of Aplysia california and co-localize with urotensin I- and urotensin II-like immunoreactivities in the cerebral ganglia.

K. Lukowiak, G. Moore, G. González, 1995, Neuroreport.

Reversed phase high pressure liquid chromatography for the identification and purification of neuropeptides.

G. Moore, 1982, Life sciences.

Designing peptide mimetics.

G. Moore, 1994, Trends in pharmacological sciences.

Tyrosinate fluorescence lifetimes for oxytocin and vasopressin in receptor-simulating environments: relationship to biological activity and 1H-NMR data.

G. Moore, J. Matsoukas, R. Turner, 1990, Biochemical and biophysical research communications.

Synthesis and biological activities of analogues of angiotensins II and III containing O-methyltyrosine and D-tryptophan.

G. Moore, J. Matsoukas, J M Matsoukas, 1985, Journal of medicinal chemistry.

Design and pharmacology of peptide mimetics.

Joshua R. Smith, J R Smith, J R Smith, 1995, Advances in pharmacology.

Receptor interactions of the position 4 side chains of angiotensin II analogues: Importance of aromatic ring quadrupole

G. Moore, J. Sandall, K Barlos, 1994, Journal of molecular recognition : JMR.

Structure elucidation and conformational analysis of gonadotropin releasing hormone and its novel synthetic analogue [Tyr(OMe)5, d-Lys6, Aze9NHEtGnRH: The importance of aromatic clustering in the receptor binding activity

G. Moore, H. Habibi, J. Matsoukas, 1998 .

Role of the amino- and carboxyl-terminal domains of thrombin receptor-derived polypeptides in biological activity in vascular endothelium and gastric smooth muscle: evidence for receptor subtypes.

M. Hollenberg, G. Moore, M. Saifeddine, 1993, Molecular pharmacology.

Submandibular gland tripeptide FEG (Phe-Glu-Gly) and analogues: keys to structure determination

G. Moore, J. Davison, R. Mathison, 2002, Peptides.

A highly specific antiserum for arginine vasopressin.

G. Burford, G. Moore, A. Lutterodt, 1977, Endocrinology.

Multiple forms of angiotensin receptors in uterine smooth muscle.

G. Moore, 1980, Canadian Journal of Physiology and Pharmacology.

The importance of the aromatic ring quadrupole for receptor interactions of the position 4 side chains of angiotensin-II analogues

P. Fowler, G. Moore, J. Matsoukas, 1994 .

NMR studies on angiotensin II: histidine and phenylalanine ring stacking and biological activity.

G. Moore, J. Matsoukas, 1984, Biochemical and biophysical research communications.

Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019

V. Apostolopoulos, G. Moore, J. Matsoukas, 2023, Biomolecules.

Methods for analyzing and interpreting cooperativity in dose-response curves--II. Partial agonists acting on muscarinic receptors in smooth muscle.

G. Moore, 1989, General pharmacology.

Proton NMR studies of angiotensin II and its analogs in aqueous solution

H. Vogel, G. Moore, N. Zhou, 1991, Journal of protein chemistry.

Network-Based Prediction of Side Effects of Repurposed Antihypertensive Sartans against COVID-19 via Proteome and Drug-Target Interactomes

Christos T. Chasapis, G. Moore, J. Matsoukas, 2023, Proteomes.

Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2

Christos T. Chasapis, V. Apostolopoulos, V. Gorgoulis, 2022, Computational and Structural Biotechnology Journal.

Synthesis and contractile activities of cyclic thrombin receptor-derived peptide analogues with a Phe-Leu-Leu-Arg motif: importance of the Phe/Arg relative conformation and the primary amino group for activity.

M. Hollenberg, G. Moore, J. Matsoukas, 1996, Journal of Medicinal Chemistry.

Role of the NH2-terminal domain of angiotensin II (ANG II) and [Sar1]angiotensin II on conformation and activity. NMR evidence for aromatic ring clustering and peptide backbone folding compared with [des-1,2,3]angiotensin II.

T Mavromoustakos, G. Moore, J. Matsoukas, 1994, The Journal of biological chemistry.

Synthesis and biological activities of angiotensin II, Sarilesin, and Sarmesin analogues containing Aze or Pip at position 7.

G. Moore, J. Matsoukas, J M Matsoukas, 1993, Journal of medicinal chemistry.

Importance of the N-terminal domain of the type II angiotensin antagonist sarmesin for receptor blockade.

G. Moore, J. Matsoukas, P. Cordopatis, 1988, Journal of medicinal chemistry.

Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides.

Theodore V. Tselios, L. Probert, G. Moore, 2000, Bioorganic & medicinal chemistry.

Classification of angiotensin receptors in rat isolated uterus, portal vein, and aorta with the novel competitive antagonist sarmesin.

G. Moore, M. N. Scanlon, 1988, Pharmacology.

Angiotensin 'antipeptides': (-)messenger RNA complementary to human angiotensin II (+)messenger RNA encodes an angiotensin receptor antagonist.

G. Moore, K. Franklin, R. Ganter, 1989, Biochemical and biophysical research communications.

Studies on molecular weights of two peptide hormones from the urophysis of white sucker (Catostomus commersoni).

G. Moore, K. Lederis, A. Letter, 1975, Canadian Journal of Biochemistry.

Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis.

T Mavromoustakos, L. Probert, G. Moore, 1999, Journal of medicinal chemistry.

Angiotensin receptors in resting smooth muscle are the low affinity sites observed in binding studies.

G. Moore, Y. Kwok, 1987, Life sciences.

Role of myelin basic protein epitope MBP74‐85 in experimental autoimmune encephalomyelitis: Elaboration of agonist and antagonist motifs

G. Moore, J. Matsoukas, J. Pires, 1999 .

Design and synthesis of small semi-mimetic peptides with immunomodulatory activity based on Myelin Basic Protein (MBP)

G. Kollias, L. Probert, G. Moore, 2005, Amino Acids.

BIOSYNTHESIS OF OXYTOCIN AND OXYTOCIN‐NEUROPHYSIN IN HOMOZYGOUS BRATTLEBORO RATS *

G. Moore, W. North, Joseph C. Rosenior, 1982, Annals of the New York Academy of Sciences.

Characterization of the "giant precursors" (70-80K) of vasopressin and oxytocin in the rat hypothalamus.

G. Moore, J. Rosenior, 1983, Progress in brain research.

Partial sequence and synthesis of urotensin I from Catastomus Commersoni

G. Moore, Ev. ko, 1982, Neuropeptides.

Photoaffinity labeling of the rat isolated portal vein: determination of affinity constants and "spare" receptors for angiotensins II and III.

G. Moore, Y. Kwok, 1984, The Journal of pharmacology and experimental therapeutics.

Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics

Christos T. Chasapis, Veroniki P. Vidali, G. Moore, 2023, International journal of molecular sciences.

Importance of the N-terminal domain of the type I angiotension II antagonist [Sar1,Ile8]ANG II for receptor blockade.

G. Moore, K. Franklin, M. H. Goghari, 2009, International journal of peptide & protein research.

Structure-activity relationships for the competitive angiotensin antagonist [sarcosine,O-methyltyrosine4]angiotensin II (sarmesin).

G. Moore, K. Franklin, M. H. Goghari, 1986, Journal of medicinal chemistry.

Structure-desensitization relationships of angiotensin analogues in the rat isolated uterus.

G. Moore, K. Franklin, M. H. Goghari, 1985, Canadian journal of physiology and pharmacology.

[Sar1Ile7]angiotensin III, a new selective antagonist of the pressor effect of angiotensin III in conscious rats.

G. Moore, C. Pang, R. Tabrizchi, 1988, Life sciences.